Edinburgh Research Explorer

Lung cancer and its association with chronic obstructive pulmonary disease

update on nexus of epigenetics

Lung cancer and its association with chronic obstructive pulmonary disease: update on nexus of epigenetics

Isaac K. Sundar[a], **Nandita Mullapudi**[b], **Hongwei Yao**[a], **Simon D. Spivack**[b], and **Irfan Rahman**[a]

[a]Department of Environmental Medicine, Lung Biology and Disease Program, University of Rochester Medical Center, Rochester

[b]Department of Pulmonary Medicine, Albert Einstein College of Medicine/Montefiore Medical Center, Price Center for Genetic & Translational Medicine, Bronx, New York, USA

Abstract

Purpose of review—Chronic obstructive pulmonary disease (COPD) and lung cancer are the leading causes of morbidity and mortality worldwide. The current research is focused on identifying the common and disparate events involved in epigenetic modifications that concurrently occur during the pathogenesis of COPD and lung cancer. The purpose of this review is to describe the current knowledge and understanding of epigenetic modifications in pathogenesis of COPD and lung cancer.

Recent findings—This review provides an update on advances of how epigenetic modifications are linked to COPD and lung cancer, and their commonalities and disparities. The key epigenetic modification enzymes (e.g. DNA methyltransferases – CpG methylation, histone acetylases/ deacetylases and histone methyltransferases/demethylases) that are identified to play an important role in COPD and lung tumorigenesis and progression are described in this review.

Summary—Distinct DNA methyltransferases and histone modification enzymes are differentially involved in pathogenesis of lung cancer and COPD, although some of the modifications are common. Understanding the epigenetic modifications involved in pathogenesis of lung cancer or COPD with respect to common and disparate mechanisms will lead to targeting of epigenetic therapies against these disorders.

Keywords

chromatin; chronic obstructive pulmonary disease; epigenetics; histones; lung cancer; methylation

Introduction

The incidence of chronic obstructive pulmonary disease (COPD) and lung cancer is among the major medical challenges, and the current research is focused on understanding the pathogenesis and therapeutic approaches of these disorders. Environmental risk factors and (epi)-genetic predisposition contribute to the development of both diseases. COPD is shown to increase the susceptibility for lung tumorigenesis up to four-fold to five-fold [1]. Furthermore, there is a shared mechanism driving the progression of both diseases [2] in which cigarette smoke-mediated oxidative stress has a major impact on the epigenome

Correspondence to Irfan Rahman, PhD, Department of Environmental Medicine, Lung Biology and Disease Program, University of Rochester Medical Center, Box 850, 601 Elmwood Avenue, Rochester, NY, USA irfan_rahman@urmc.rochester.edu.

leading to epigenetic modifications, compared to genetic (inherited germline sequence-based) susceptibility which occurs only approximately 1% of smokers. The current research is focused on identifying the common and disparate events involved in epigenetic modifications that concurrently occur between COPD and lung cancer. This review focuses on current knowledge of specific processes or molecules that are at the nexus of COPD and lung cancer, with particular emphasis on shared or common and disparate epigenetic alterations via histone modification enzymes, but not by other regulatory elements, such as microRNAs.

Chromatin remodeling or epigenetic modifications

Cigarette smoke is the cause of 80–90% cases of COPD and lung cancer because, in part, of its ability to induce oxidative stress and inflammation either directly by inhaled oxidants or influx of inflammatory cells in the lung. Oxidative stress and inflammatory response eventually then alter the redox status of the cells leading to destabilization of the genome culminating in epigenetic modifications.

Histone tails are modified by an extensive group of nonhistone chromatin-associated proteins called chromatin-modifying enzymes, which exist in cells as multicomponent protein complexes that are frequently recruited to chromatin in association with DNA-bound transcription factors [3]. Various covalent post-translational modifications (PTMs) in histones and associated regions of DNA play vital roles in genomic functions by binding specific transcription factors and co-activators, which in turn serve to alter the structural property of chromatin [4].

The chromatin modification enzymes are classified into several enzyme classes based on their functions: acetylation by histone acetyltransferases (HATs), deacetylation by histone deacetylases (HDACs), methylation by histone methyltransferases (HMTs), and demethylation by histone demethylases (HDMs) (Fig. 1). The resulting PTMs may act alone or in concert to facilitate the activation or repression of chromatin-mediated gene expression for inflammatory mediators, genes for cell cycle arrest, apoptosis, senescence, anti-oxidants, growth factors, and tumor suppressor genes involved in COPD and lung cancer [5,6]. The possible link for specific epigenetic modifications on genes involved in the above events in different disease phenotypes might be due to the environment and alterations in gene expression patterns [7], which occurs in patients with COPD and lung cancer.

CpG methylation: role of DNA methyltransferases

Lung cancer exhibits profound alterations in chromatin structure. Genome-wide DNA demethylation with site-specific hypermethylation occurs in the bronchial epithelium of smokers, lung cancer cells, and lung tumors [8,9,10••]. Clinical data from patients with lung cancer demonstrated that the overexpression of DNA methyl-transferase 1 (DNMT1), which catalyzes methylation of DNA in CpG islands, was associated with p53 mutation and increased expression of specificity protein 1 (Sp1) [11]. Nicotine-derived nitrosamine ketone (NNK)-induced activation of DNMT1 causes epigenetic alterations, such as hypermethylation of promoters of multiple tumor suppressor genes leading to lung tumorigenesis and poor prognosis, thus providing an important link between tobacco smoking and lung cancer [12•].

There are conflicting reports in the literature regarding the relationship between gene-specific DNA methylation and smoking [13]. Studies in methylation from lung tissue of non-small cell lung cancer (NSCLC) patients showed no significant association between smoking history and promoter hypermethylation in the genes *APC1* [14], *DAPK* [15], and *p16* [16]. On the contrary, significant associations between promoter hypermethylation and

with smoking history has been reported in NSCLC patients in *CDKN2A* [17–19], *HIC1* [20], *HtrA3* [21], and *CHFR* [22].

There are several reports that describe promoter hypermethylation and associated gene-silencing of various genes in lung cancer [8]. Several of these studies likely include a subset of COPD patients; however, they are not typically studied separately to identify COPD-specific signals. The identification of CpG methylation events in COPD as precursor events in lung cancer could have predictive clinical significance. It is plausible that genes which are involved in COPD pathways would represent commonalities in their regulation, including possible silencing via CpG hypermethylation. Examples of such candidate genes that have been reported as hypermethylated in lung cancer or COPD are listed in Table 1 [23•,24–30,31•].

Histone acetyltransferases

Cigarette smoke induces acetylation of histone H3 in macrophages and in lung of humans and rodents, which implies that histone acetylation plays a vital role in chromatin remodeling, and is subsequently associated with sustained lung inflammatory response in patients with COPD [32–35]. Global HAT activity does not change despite acetylation of histones H3 and H4 on specific lysine residues in response to cigarette smoke in mouse lungs [32,35], and in lungs of smokers and COPD patients [34,36]. CREB-binding protein (CBP) and p300 are the key transcriptional co-activators regulated by mitogen-activated protein kinase (MAPK), and possess intrinsic HAT activity [37–39]. A recent study demonstrated the role of protein kinase C zeta in cigarette smoke or reactive aldehydes and bacterial lipopolysaccharide (LPS)-induced lung inflammation via CBP-mediated acetylation of RelA/p65 causing histone phosphorylation and acetylation on promoters of pro-inflammatory genes [40•]. Cigarette smoke-derived oxidants activate IKKα and phosphorylate RelA/p65 (Ser276) and histone H3 (Ser10), and acetylate histone H3 (Lys9) by interacting with RelA/p65 and CBP/p300 [35,41].

CBP gene alterations include mutations and deletions detected in lung cancer cell lines, as well as in surgical specimens from patients with lung cancer, suggesting the role of CBP in the tumorigenesis and/or progression of a subset of lung cancers [42]. Horwitz *et al.* [43] reported that adenovirus E1A interacts with histone modification enzymes possibly via CBP/p300, forming a basis for global epigenetic modifications that leads to cellular transformation particularly seen in lung of patients with COPD and lung cancer. Hence, development of small molecule inhibitors against various HATs including co-activators (p300, CBP, PCAF, and GCN5) may be potential targets for pharmacological and therapeutic applications to treat COPD and lung cancer [44,45] (Table 2).

Histone deacetylases

Reduction of HDACs, particularly HDAC2, is associated with steroid resistance in COPD. The levels and activities of histone deacetylases, particularly HDAC2 [36,46,47] and sirtuin 1 (SIRT1), are reduced in lungs and alveolar macrophages of patients with COPD [48,49]. A recent study showed the role of the HDAC2–Nrf2 axis on steroid resistance to control lung inflammatory response [50•]. Reduction in HDAC2 levels or activity leads to acetylation of NF-κB and glucocorticoid receptor α, resulting in abnormal inflammatory response and steroid resistance in lungs of patients with COPD [51] (Table 2). Restoring HDAC2/SIRT1 levels or activities will have a significant impact on steroid efficacy, thus inhibiting chronic inflammatory response in COPD [52,61,62].

In contrast, alterations in expression and somatic gene mutations encoding HDACs have been linked to tumor progression and aberrant transcription of key genes regulating

important cellular functions, such as cell proliferation, cell cycle regulation, and apoptosis [63]. Aberrant expression of HDACs is implicated in the progression of tumorigenesis as well as in metastatic phenotypes. Examples of this include increased HDAC1, and decreased HDAC5 and HDAC10 expression correlated with advanced stages of disease with adverse outcome in lung cancer patients [53] (Table 2). Another study showed the involvement of HDAC6 in epithelial–mesenchymal transition of lung cancer cell metastasis *in vitro* via the TGF-β SMAD3 signaling cascade [64]. Recently, Haberland *et al.* [65] using a genetic approach found that deletion of single class I HDAC is not sufficient to cause cell death but both HDAC1 and HDAC2 play redundant and essential roles in the survival of tumor cells, as well as in DNA-damage response by promoting double-strand break repair. This provides deeper insight into the radio-sensitizing effects of a combination of HDAC inhibitors (HDACi) that are under development for cancer therapies [66••]. Further studies are required to understand the mechanism of such disparity in HDAC regulation in lung cancer and COPD.

Histone methyltransferases

HMTs are deregulated in several types of cancers and thus affect the global methylation levels. Methylation at H3K4, H3K36, and H3K79 is linked to gene activation, whereas H3K9, H3K27, and H3K20 methylation is associated with gene repression [67]. Loss of trimethylation of histone H3K20 in selective tumor cells [68] and in-vivo demonstration of HMT SUV39H deficiency sensitizes mice to tumorigenesis [54]. These findings provide evidence that alterations in histone methylation may play a vital role in tumor onset and/or progression [69].

Epigenetic silencing of *CXCL14* by histone methylation in sputum samples of early-stage asymptomatic lung cancer patients were associated with increased (2.9-fold) risk of lung cancer compared to the controls [70]. Protein arginine *N*-methyltransferases (PRMTs), such as PRMT1 and PRMT6, have been identified to play a role in carcinogenesis [55], but no information is available in lung cancer. Liu *et al.* [71] established an in-vitro system to examine the effects of cigarette smoke-induced cancer-associated epigenomic alterations, such as decreased levels of H4K16ac and H4K20me3, but increased relative levels of H3K27me3 coincided with decreased DNMT1 and increased DNMT3b expression in cultured normal human small airway epithelial cells and cdk-4/hTERT-immortalized human bronchial epithelial cells. These features help to delineate some early epigenetic mechanisms regulating gene expression during lung cancer development [56,71] (Table 2).

Histone demethylases

The HDMs are classified into two kinds, such as lysine-specific demethylase 1 (LSD1) and Jumonji C (JmjC) domain family proteins involved in the regulation of gene expression [72]. Aberrant expression of HDMs is manifested during the course of tumor initiation and progression [73]. The role of HDMs in lung cancer and COPD is not known though hypoxia, which is known to occur in the tumor microenvironment and in lungs of patients with COPD, alters HDMs, such as JMJD1A, JMJD2B, and JARID1A [57•–59•].

A recent report showed the involvement of another HDM, JARID1B (KDM5B), in growth of cancer cells through the E2F/RB1 cell cycle regulation pathway in various cancer cell lines. Microarray analysis and immunohistochemistry revealed an elevated expression of KDM5B in lung tumor tissues of both NSCLC and SCLC compared to non-neoplastic tissues, suggesting the role of JARID1B overexpression in lung carcinogenesis [60]. Thus, the inhibition of histone demethylase represents a viable tool in epigenetic therapeutics potentiating the activity of hypomethylating agents [74] (Table 2).

Conclusion

Cigarette smoke-mediated alterations in histone modification enzymes and molecules are linked to molecular and cellular functions such as post-translational modifications of histones, gene expression of inflammatory mediators, cell cycle arrest, apoptosis, senescence, autophagy, unfolded protein response, antioxidants or stress response, growth factors, and tumor suppressor genes, and DNA replication, recombination, and repair. Understanding the epigenetic mechanisms that influence the human genome based on the effects from the environment results in transcriptional activation of specific genes, at a specific time point, in specific cell types or organs are the important areas of further research in development and progression of COPD and lung cancer. This understanding will lead to a deeper insight into identifying the potential link between CpG methylation, chromatin modification enzymes, and microRNAs (which modulate certain DNMTs) implicated in the pathogenesis of cigarette smoke or environmental stress-mediated chronic lung diseases such as COPD and lung cancer [75]. Further studies on the molecular mechanisms underlying histone modification enzymes involved in chromatin modification will provide insights into specific therapeutic targets based on either common and/or disparate mechanisms and devising treatment strategies based on epigenetics against lung cancer and COPD.

Acknowledgments

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

• of special interest

•• of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 294–295).

1. Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003; 163:1475–1480. [PubMed: 12824098]

2. Yao H, Rahman I. Current concepts on the role of inflammation in COPD and lung cancer. Curr Opin Pharmacol. 2009; 9:375–383. [PubMed: 19615942]

3. Berger SL. Histone modifications in transcriptional regulation. Curr Opin Genet Dev. 2002; 12:142–148. [PubMed: 11893486]

4. Ruthenburg AJ, Li H, Patel DJ, et al. Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol. 2007; 8:983–994. [PubMed: 18037899]

5. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007; 447:407–412. [PubMed: 17522673]

6. Guil S, Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol. 2009; 41:87–95. [PubMed: 18834952]

7. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat Rev Genet. 2007; 8:253–262. [PubMed: 17363974]

8. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer. 2004; 4:707–717. [PubMed: 15343277]

9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349:2042–2054. [PubMed: 14627790]

10••. Liu F, Killian JK, Yang M, et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene. 2010; 29:3650–3664. This study provides evidence that cigarette smoke mediates 'cancer-associated' epigenomic alterations in cultured human lung epithelial cells. Thus, in-vitro studies may have significant impact on delineating the early epigenetic mechanisms regulating gene expression during pulmonary carcinogenesis. [PubMed: 20440268]

11. Lin RK, Wu CY, Chang JW, et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res. 2010; 70:5807–5817. [PubMed: 20570896]

12•. Lin RK, Hsieh YS, Lin P, et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. J Clin Invest. 2010; 120:521–532. This study provides cell, animal, and clinical evidence that NNK induces DNA methyltransferase 1 via AKT/GSK3β/βTrCP/hnRNP-U signaling pathway to demonstrate the mechanism in smoking-mediated lung cancer. [PubMed: 20093774]

13. Tsou JA, Hagen JA, Carpenter CL, et al. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002; 21:5450–5461. [PubMed: 12154407]

14. Brabender J, Usadel H, Danenberg KD, et al. Adenomatous polyposis coli gene promoter hypermethylation in nonsmall cell lung cancer is associated with survival. Oncogene. 2001; 20:3528–3532. [PubMed: 11429699]

15. Kim DH, Nelson HH, Wiencke JK, et al. Promoter methylation of DAP-kinase: association with advanced stage in nonsmall cell lung cancer. Oncogene. 2001; 20:1765–1770. [PubMed: 11313923]

16. Sanchez-Cespedes M, Decker PA, Doffek KM, et al. Increased loss of chromosome 9p21 but not p16 inactivation in primary nonsmall cell lung cancer from smokers. Cancer Res. 2001; 61:2092–2096. [PubMed: 11280771]

17. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in nonsmall cell lung cancer. Cancer Res. 2001; 61:3419–3424. [PubMed: 11309302]

18. Kersting M, Friedl C, Kraus A, et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol. 2000; 18:3221–3229. [PubMed: 10986054]

19. Hou M, Morishita Y, Iljima T, et al. DNA methylation and expression of p16(INK4A) gene in pulmonary adenocarcinoma and anthracosis in background lung. Int J Cancer. 1999; 84:609–613. [PubMed: 10567907]

20. Eguchi K, Kanai Y, Kobayashi K, et al. DNA hypermethylation at the D17S5 locus in nonsmall cell lung cancers: its association with smoking history. Cancer Res. 1997; 57:4913–4915. [PubMed: 9354457]

21. Beleford D, Liu Z, Rattan R, et al. Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Clin Cancer Res. 2010; 16:398–409. [PubMed: 20068077]

22. Takeshita M, Koga T, Takayama K, et al. CHFR expression is preferentially impaired in smoking-related squamous cell carcinoma of the lung, and the diminished expression significantly harms outcomes. Int J Cancer. 2008; 123:1623–1630. [PubMed: 18623126]

23•. Suzuki M, Wada H, Yoshino M, et al. Molecular characterization of chronic obstructive pulmonary disease-related nonsmall cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol. 2010; 17:878–888. This study identifies two genes (*IL-12Rb2* and *Wif-1*) from a panel of 12 for which promoter hypermethylation was significantly associated with COPD when compared to non-COPD study participants. It is one of the few studies that examine methylation events specifically associated with COPD in NSCLC patients. [PubMed: 19841986]

24. Wang R, An J, Ji F, et al. Hypermethylation of the *Keap1* gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun. 2008; 373:151–154. [PubMed: 18555005]

25. Shames DS, Girard L, Gao B, et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 2006; 3:e486. [PubMed: 17194187]

26. Dammann R, Strunnikova M, Schagdarsurengin U, et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer. 2005; 41:1223–1236. [PubMed: 15911247]

27. Luxen S, Belinsky SA, Knaus UG. Silencing of DUOX NADPH oxidases by promoter hypermethylation in lung cancer. Cancer Res. 2008; 68:1037–1045. [PubMed: 18281478]

28. Harden SV, Tokumaru Y, Westra WH, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res. 2003; 9:1370–1375. [PubMed: 12684406]

29. Shivapurkar N, Stastny V, Okumura N, et al. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res. 2008; 68:7448–7456. [PubMed: 18794132]

30. Zelko IN, Mueller MR, Folz RJ. CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic Biol Med. 2010; 48:895–904. [PubMed: 20079429]

31•. Sood A, Petersen H, Blanchette CM, et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. Am J Respir Crit Care Med. 2010; 182:1098–1104. This study demonstrates a significant association between smokers with CpG methylation at the *p16* and *GATA4* genes and lowered lung function when compared to smokers without these epigenetic changes. It is one of the few studies that examine methylation events specifically associated with COPD particularly in response to wood smoke. [PubMed: 20595226]

32. Marwick JA, Kirkham PA, Stevenson CS, et al. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol. 2004; 31:633–642. [PubMed: 15333327]

33. Rahman I. Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. J Biochem Mol Biol. 2003; 36:95–109. [PubMed: 12542980]

34. Szulakowski P, Crowther AJ, Jimenez LA, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 174:41–50. [PubMed: 16574938]

35. Yang SR, Valvo S, Yao H, et al. IKK alpha causes chromatin modification on pro-inflammatory genes by cigarette smoke in mouse lung. Am J Respir Cell Mol Biol. 2008; 38:689–698. [PubMed: 18239189]

36. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005; 352:1967–1976. [PubMed: 15888697]

37. Thomson S, Clayton AL, Hazzalin CA, et al. The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J. 1999; 18:4779–4793. [PubMed: 10469656]

38. Bedford DC, Kasper LH, Fukuyama T, et al. Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. Epigenetics. 2010; 5:9–15. [PubMed: 20110770]

39. Chen L, Fischle W, Verdin E, et al. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science. 2001; 293:1653–1657. [PubMed: 11533489]

40•. Yao H, Hwang JW, Moscat J, et al. Protein kinase C zeta mediates cigarette smoke/aldehyde- and lipopolysaccharide-induced lung inflammation and histone modifications. J Biol Chem. 2010; 285:5405–5416. This study demonstrates a novel role of PKCζ in cigarette smoke/aldehyde-mediated and LPS-mediated inflammatory response and chromatin modifications in the lungs. These findings also provide new insights on the molecular mechanisms underlying the pathogenesis of chronic lung diseases. [PubMed: 20007975]

41. Gloire G, Horion J, El Mjiyad N, et al. Promoter-dependent effect of IKKalpha on NF-kappaB/p65 DNA binding. J Biol Chem. 2007; 282:21308–21318. [PubMed: 17537731]

42. Kishimoto M, Kohno T, Okudela K, et al. Mutations and deletions of the *CBP* gene in human lung cancer. Clin Cancer Res. 2005; 11:512–519. [PubMed: 15701835]

43. Horwitz GA, Zhang K, McBrian MA, et al. Adenovirus small e1a alters global patterns of histone modification. Science. 2008; 321:1084–1085. [PubMed: 18719283]

44. Dekker FJ, Haisma HJ. Histone acetyl transferases as emerging drug targets. Drug Discov Today. 2009; 14:942–948. [PubMed: 19577000]

45. Tjeertes JV, Miller KM, Jackson SP. Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J. 2009; 28:1878–1889. [PubMed: 19407812]

46. Adenuga D, Yao H, March TH, et al. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Respir Cell Mol Biol. 2009; 40:464–473. [PubMed: 18927347]

47. Yang SR, Chida AS, Bauter MR, et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol. 2006; 291:L46–L57. [PubMed: 16473865]

48. Nakamaru Y, Vuppusetty C, Wada H, et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 2009; 23:2810–2819. [PubMed: 19376817]

49. Rajendrasozhan S, Yang SR, Kinnula VL, et al. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 177:861–870. [PubMed: 18174544]

50•. Adenuga D, Caito S, Yao H, et al. Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction. Biochem Biophys Res Commun. 2010; 403:452–456. Important finding showing that loss of HDAC2 is a critical factor in inhaled toxicant-mediated lung inflammation especially in regulating the anti-inflammatory effects of glucocorticoids in mouse lungs. This may have implications for devising better therapies for steroid insensitive patients to treat chronic lung diseases. [PubMed: 21094147]

51. Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 2006; 203:7–13. [PubMed: 16380507]

52. Meja KK, Rajendrasozhan S, Adenuga D, et al. Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. Am J Respir Cell Mol Biol. 2008; 39:312–323. [PubMed: 18421014]

53. Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer. 2004; 112:26–32. [PubMed: 15305372]

54. Peters AH, O'Carroll D, Scherthan H, et al. Loss of the Suv39H histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001; 107:323–337. [PubMed: 11701123]

55. Litt M, Qiu Y, Huang S. Histone arginine methylations: their roles in chromatin dynamics and transcriptional regulation. Biosci Rep. 2009; 29:131–141. [PubMed: 19220199]

56. Spannhoff A, Heinke R, Bauer I, et al. Target-based approach to inhibitors of histone arginine methyltransferases. J Med Chem. 2007; 50:2319–2325. [PubMed: 17432842]

57•. Yang J, Jubb AM, Pike L, et al. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 2010; 70:6456–6466. This study highlights that histone demethylase JMJD2B is regulated by both estrogen receptor α and hypoxia-inducible factor 1α, and drives breast cancer cell proliferation in normoxia and hypoxia. Thus, targeting histone demethylase in hypoxic condition which occurs in lung cancer may be crucial. [PubMed: 20682797]

58•. Krieg AJ, Rankin EB, Chan D, et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol. 2010; 30:344–353. This study demonstrates that loss of *JMJD1A* is sufficient to reduce tumor growth *in vivo*, and histone demethylation plays a significant role in modulating growth within the tumor microenvironment. [PubMed: 19858293]

59•. Zhou X, Sun H, Chen H, et al. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase. Cancer Res. 2010; 70:4214–4221. This study highlights that hyperoxia leads to induction of global as well as gene-specific H3K4me3 in normal human bronchial epithelial cells and human lung carcinoma cells, which plays a vital role in hyperoxia-induced altered gene expression and tumor progression. [PubMed: 20406991]

60. Hayami S, Yoshimatsu M, Veerakumarasivam A, et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer. 2010; 9:59. [PubMed: 20226085]

61. Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004; 200:689–695. [PubMed: 15337792]

62. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002; 99:8921–8926. [PubMed: 12070353]

63. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007; 1:19–25. [PubMed: 19383284]

64. Shan B, Yao TP, Nguyen HT, et al. Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial–mesenchymal transition. J Biol Chem. 2008; 283:21065–21073. [PubMed: 18499657]

65. Haberland M, Johnson A, Mokalled MH, et al. Genetic dissection of histone deacetylase requirement in tumor cells. Proc Natl Acad Sci U S A. 2009; 106:7751–7755. [PubMed: 19416910]

66••. Miller KM, Tjeertes JV, Coates J, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol. 2010; 17:1144–1151. This study describes the importance of HDAC1 and HDAC2 in DNA-damage response by promoting double-strand break repair. Findings from this study provides better insights on the radio-sensitizing effects of HDAC inhibitors against cancer therapy. [PubMed: 20802485]

67. Kouzarides T. Chromatin modifications and their function. Cell. 2007; 128:693–705. [PubMed: 17320507]

68. Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005; 37:391–400. [PubMed: 15765097]

69. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009; 8:1409–1420. [PubMed: 19509247]

70. Tessema M, Klinge DM, Yingling CM, et al. Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosis. Oncogene. 2010; 29:5159–5170. [PubMed: 20562917]

71. Liu H, Zhou Y, Boggs SE, et al. Cigarette smoke induces demethylation of prometastatic oncogene synuclein-gamma in lung cancer cells by down-regulation of DNMT3B. Oncogene. 2007; 26:5900–5910. [PubMed: 17369845]

72. Tian X, Fang J. Current perspectives on histone demethylases. Acta Biochim Biophys Sin (Shanghai). 2007; 39:81–88. [PubMed: 17277881]

73. Lim S, Janzer A, Becker A, et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis. 2010; 31:512–520. [PubMed: 20042638]

74. Grant S. Targeting histone demethylases in cancer therapy. Clin Cancer Res. 2009; 15:7111–7113. [PubMed: 19934292]

75. Schwartz DA. Epigenetics and environmental lung disease. Proc Am Thorac Soc. 2010; 7:123–125. [PubMed: 20427583]

Key points

- This review highlights the importance of epigenetic alterations mediated by chromatin modification enzymes that are at the nexus of chronic obstructive pulmonary disease (COPD) and lung cancer.

- Post-translational modification of histones facilitates activation or repression of genes linked to pathogenesis of COPD and lung cancer.

- DNA methyltransferases, causing hypermethylation of genes and promoters, histone acetyltransferases and histone deacetylases play a crucial role in opening and closing the chromatin to modulate gene expression.

- Histone methyltransferases and histone demethylases are vital to maintain the structure of hetero-chromatin, which is implicated in pathogenesis of COPD and lung cancer.

- Understanding the signaling molecules and pathways involved in epigenetic modifications will provide a new insight to help identify therapeutic targets and devise therapies based on epigenetics against these disorders.

Figure 1.
Major chromatin modification enzymes involved in posttranslational modification of histones in chronic obstructive pulmonary disease and lung cancer

Table 1

Examples of candidate genes methylated and their functions in chronic obstructive pulmonary disease and lung cancer

Gene name	Function	References
IL-12Rβ2, *Wif-1*	Cell transduction/signaling genes involved in the development of COPD-related NSCLC	[23•]
KEAP1	Redox-sensitive transcription factor regulates antioxidant genes	[24]
SERPINB5	Serpin peptidase inhibitor	[25]
TIMP3, *TIMP4*	Tissue inhibitor of metalloproteinase 3 and 4, involved in degradation of extracellular matrix	[26]
DUOX1, *DUOX2*	Dual oxidases: hydrogen peroxide production and host defense in airways	[27]
GSTP1	Glutathione-S-peroxidase, local detoxification and protective function in lung	[28]
CYGB	Detoxification of reactive species	[29]
ECSOD	Maintenance of normal redox homeostasis in the lung	[30]
P16, *GATA4*	Cell transduction/signaling	[31•]

COPD, chronic obstructive pulmonary disease; NSCLC, non-small cell lung cancer.

Table 2

Chromatin modification enzymes, associated histone modifications and their role in chronic obstructive pulmonary disease and cancer

Enzymes	Cigarette smoke/COPD	Cancer	Role in cigarette smoke/COPD and cancer	References
DNA methyltransferase				
DNMTs	DNMT1↓, DNMT3b↑	DNMT1↑, H4K16ac↓, H4K20me3↓, H3K27me3↑	Regulate gene expression in lung cancer development	[10••,12•]
Histone acetyltransferases				
CBP/p300	H3S10↑, H3K9ac↑	H3K9ac↓, H3K56ac↓	Chromatin remodeling and sustained inflammatory response in COPD. Interaction of E1A and p300 in prostate cancer and cellular transformation. DNA damage response in human cell lines	[32,39,40•,42,45]
GCN5	–			
Histone deacetylases				
HDACs	HDAC2↓, SIRT1↓	SIRT1↓, HDAC1↑, HDAC5↓, HDAC10↓	Abnormal inflammatory response and steroid resistance. Aberrant expression of HDACs in tumor progression	[36,46–49,50•,51–53]
Histone methyltransferases				
SUV39H	–	SUV39H↓	Impairs heterochromatin and genome stability	[54]
PRMTs	–	PRMT1↑, PRMT6↑	Role in growth and regulation of cancer cells	[55,56]
Histone demethylases				
JMJD2B	–	JMJD2B↑	Hypoxia dependent HIF-1α and ERα signaling regulates histone methylation in hypoxia. Hypoxia-mediated global activation of H3K4me3 involved in growth of cancer cells through E2F/RB1 cell cycle regulation pathway in NSCLC and SCLC	[57•]
JMJD1A	–	–		[58•]
JARID1A	–	H3K4me3↑		[59•]
JARID1B		JARID1B↑		[60]

COPD, chronic obstructive pulmonary disease; DNMT, DNA methyltransferase; HDAC, histone deacetylase; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.